Labiofam set to build pharmaceutical plant in Bolivia

posted by Phill Allen

October, 01st, 2014

Company News

The Cuban state-owned pharmaceutical and chemical company, Labiofam, is set to build a plant in Bolivia.
Labiofam to build plant
The project, which came at the behest of Bolivian President Evo Morales, is designed to enable the South American country to independently meet 100% of its demand for basic medicine.
“We should sign the contract at the end of this month,” Labiofam director general, Jose Antonio Fraga, told Reuters. “If we sign the contract we will start right away.”
“This is basically for poor people because they can’t afford the prices set by the transnationals,” explained Mr Fraga. “So these industries will be subsidized by the state or their products will be sold at a very small profit margin, just to sustain themselves, not to get rich.”
Bolivia aims to put the plant to work in supplementing existing supplies and meeting 100% of its domestic demand for basic medicine.
Reports suggest that any excess production made by the plant would be exported, in the main, to countries within the Bolivarian Alliance for the Peoples of America (ALBA).
The Fund for the Productive Industrial Revolution (FINPRO) was created by the Bolivian government in 2012 to finance such projects.

Related reading:

TAGS: Bolivia, Labiofam, pharmaceutical plant,

SHARE:

Avatar photo

Author

Phill Allen

Managing Director

An in and outside the (bioprocess) box thinker, fluid management specialist Phill knows a thing or two about keeping pharma liquid logistics flowing.

10 Times Products Hilariously Knocked-Off Famous Brands 
Company News Pharmaceutical Industry News Product News

10 Times Products Hilariously Knocked-Off Famous Brands 

Inspired (or uninspired) by poor knocked-off versions of ALLpaQ bioprocess containers, we take a look at the funnier side of […]

Mar 20th, 2023

Innovation Not Imitation: Every Masterpiece Has Its Cheap Copy
Company News Pharmaceutical Industry News Product News

Innovation Not Imitation: Every Masterpiece Has Its Cheap Copy

Mar 16th, 2023